Pituitary and SARS CoV-2: an unremitting conundrum

Elsevier

Available online 27 February 2023, 101752

Best Practice & Research Clinical Endocrinology & MetabolismAuthor links open overlay panel, , Abstract

There is an increased interest in the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are both acute and delayed effects on pituitary, related to infection and/or treatment. Hypopituitarism, pituitary apoplexy and hypophysitis have been all reported, as well as arginine vasopressin deficiency (diabetes insipidus) and syndrome of inappropriate antidiuretic hormone secretion. Furthermore, patients with acromegaly, Cushing’s disease and hypopituitarism are theoretically at increased risk of complications with COVID-19 and need close monitoring. Evidence regarding pituitary dysfunction in patients with COVID-19 continues to be gathered, as the breadth and depth of knowledge also continues to rapidly evolve. This review summarizes data analysis to date on the possible effects of COVID-19 and COVID-19 vaccination on normal pituitary and patients with known pituitary pathology. Though clinical systems were significantly affected, it seems there was no overall loss of biochemical control in patients with certain pituitary pathologies.

Keywords

COVID-19

SARS-CoV-2 infection

Cushing’s

acromegaly

hypopituitarism

pituitary

View Abstract

© 2023 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif